Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 7Phase 1/2 7Phase 1 5Phase NA 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 1

Conditions

Colorectal Neoplasms 3Sarcoma, Ewing 1Sarcoma 1Rectal Neoplasms 1Neoplasm Metastasis 1Colonic Neoplasms 1

Interventions

Specimen Handling 150pembrolizumab 132Magnetic Resonance Spectroscopy 120Cyclophosphamide 118Biopsy 106fludarabine 90Nivolumab 61Carboplatin 55Radiotherapy 49Cisplatin 49Gemcitabine 48venetoclax 43Paclitaxel 43Cetuximab 40fludarabine phosphate 39Ipilimumab 36Fluorouracil 35atezolizumab 34Bevacizumab 33durvalumab 30Radiation 30Oxaliplatin 29X-Rays 28Leucovorin 28Dexamethasone 28Azacitidine 27Irinotecan 26Cytarabine 26Radiosurgery 24Injections 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × trifluridine tipiracil drug combination × 90 days × Clear all
NCT03715933 2026-05-22

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Inhibrx Biosciences, Inc

Phase 1 Recruiting
411 enrolled
Sarcoma

Sarcoma, Sarcoma, Ewing

NCT04920032 2026-05-11

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

University of California, Irvine

Phase 1 Recruiting
22 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04511039 2026-05-04

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Roswell Park Cancer Institute

Phase 1 Recruiting
45 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04868773 2026-04-24

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

University of California, Irvine

Phase 1 Completed
15 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT04104139 2026-04-15

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

OHSU Knight Cancer Institute

Phase 1 Active not recruiting
19 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡